Serum Levels of Soluble Fms like Tyrosine Kinase-1(sFlt-1) in Normotensive and Preeclamptic Pregnancy

  • Dr Sonali Yadav Ph.D, Department of Pathology, King George’s Medical University, Lucknow, Uttar Pradesh, India
  • Dr Yogendra Singh M.D, Department of Medicine, King George’s Medical University, Lucknow, Uttar Pradesh, India
  • Dr S.M. Natu Ph.D, Department of Pathology, King George’s Medical University, Lucknow, Uttar Pradesh, India
  • Dr M.M. Goel M.D, Department of Pathology, King George’s Medical University, Lucknow, Uttar Pradesh, India
  • Dr Urmila Singh M.D, Department of Obstetrics and Gynecology, King George’s Medical University, Lucknow, Uttar Pradesh, India
  • Dr Pushpa Tondon Ph.D, Department of Pathology, King George’s Medical University, Lucknow, Uttar Pradesh, India
DOI: https://doi.org/10.17511/ijmrr.2013.i03.07
Keywords: Pregnancy, Preeclampsia, Soluble Fms like Tyrosine Kinase-1

Abstract

Background: The study aimed to measure serum levels of sFlt-1 throughout pregnancy in normotensive and preeclamptic women and to determine if sFlt-1 concentrations alter before the clinical manifestation of the condition.

Material and Methods: It was a nested case control study. Serum samples were collected during pregnancy at three different gestational periods (12-20 weeks, 21-28 weeks and 29- till term) and one sample post delivery, from within the cohort of pregnant women reporting to antenatal clinic. The subjects were divided in to normotensive (controls) and preeclamptic (cases) groups. Circulating levels of antiangiogenic (sFlt-1) were analyzed by enzyme linked immunosorbent assay (ELISA).

Results: Maternal serum concentrations of sFlt-1 increased with the advancement of gestation age in both normotensive and preeclamptic pregnancies but significantly more increased levels were observed in preeclamptic pregnancies as compared with normotensive pregnancies.

Conclusion: Maternal circulating sFlt-1 concentrations were significantly higher in women with preeclampsia, which may contribute to the development of preeclampsia.

Downloads

Download data is not yet available.

References

1. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. Jul 2000; 183(1): S1-S22. [PubMed]

2. Williams D. Long-term complications of pre-eclampsia. Semin Nephrol. 2011; 31(1):111–22. [PubMed]

3. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Ann Rev Pathol 2010; 5:173–192. [PubMed]

4. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A.1993;90:10705 10709. [PubMed]

5. He Y, Smith SK, Day KA, Clark DE, Licence DR, Charnock-Jones DS. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity.Mol Endocrinol. 1999;13:537–545. [PubMed]

6. Vuorela P, Helske S, Hornig C, Alitalo K, Weich H,Halmesma¨ki E. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preelcampsia. Obstet Gynecol 2000;95:353-7.

7. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA.. Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003 Mar;111(5):649-58.

8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of pre-eclampsia. N Engl J Med. 2004 Feb 12;350(7):672-8. [PubMed]

9. Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS. Low maternal serum levels of pla-centa growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol 2001; 184: 1267-72. [PubMed]

10. Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004; 23: 101-11.

11. Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for pre-eclampsia. J Clin Endocrinol Metab. 2004 Feb;89(2):770-5. [PubMed]

12. Powers RW, Roberts JM, Cooper KM, Gallaher MJ, Frank MP, Harger GF, Ness RB. Maternal serum soluble fms-like tyrosine kinase 1 concentrations are not increased in early pregnancy and decrease more slowly postpartum in women who develop pre-eclampsia. Am J Obstet Gynecol 2005;193(1):185-91.

13. Hertig A, Berkane N, Lefevre G, Toumi K, Marti HP, Capeau J, Uzan S, Rondeau E. Maternal Serum sFlt1Concentration is an early and reliable predictive marker of preeclampsia. Clin Chem. 2004 Sep;50(9):1702-3. [PubMed]

14. Rajakumar A, Michael HM, Rajakumar PA, Shibata E, Hubel CA, Karumanchi SA, et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta. 2005 Aug; 26(7): 563-73.
CITATION
DOI: 10.17511/ijmrr.2013.i03.07
Published: 2013-08-31
How to Cite
1.
Yadav S, Singh Y, Natu S, Goel M, Singh U, Tondon P. Serum Levels of Soluble Fms like Tyrosine Kinase-1(sFlt-1) in Normotensive and Preeclamptic Pregnancy. Int J Med Res Rev [Internet]. 2013Aug.31 [cited 2024Nov.22];1(3):114-9. Available from: https://ijmrr.medresearch.in/index.php/ijmrr/article/view/18
Issue
Vol 1 No 3 (2013): Jul-Aug
Section
Original Article

Most read articles by the same author(s)